COTC024: Defining PK and Biological Activity of Systemic Oncolytic Vesicular Stomatitis Virus (VSV) within a Dose/Schedule Optimization Study

Patient Disease:

Canine T Cell Lymphoma 

Study Name:

COTC024: Defining PK and Biological Activity of Systemic Oncolytic VSV within a Dose/Schedule Optimization Study 

Purpose of the study:

  • To define optimal dose and schedule of administration for systemic VSV treatment in dogs with cancer.

  • VSV is a naturally oncolytic virus that has been engineered to possess potent anti-cancer properties with enhanced safety.

Primary Eligibility Criteria:

  • Dogs that weigh at least 20 kg (44lb)

  • Diagnosis of T cell lymphoma

  • Dogs must be feeling well, with adequate routine blood work (blood count, chemistry profile, urinalysis)

  • Dogs must be up to date on all routine vaccinations and parasite control

  • Two week washout from chemotherapy, 6 weeks from radiation therapy, 72 hours from steroids

Study Protocol:

  • Determine eligibility with initial screening: physical exam, blood tests (CBC, biochemistry, urinalysis), confirmation of T cell lymphoma diagnosis, and chest x-rays

  • 1st day of study: Pre-treatment physical exam, tumor measurements, blood samples, lymph node biopsy

  • 2nd day of study: Virus administration, monitoring and blood sampling; must stay hospitalized overnight

  • 3rd & 4th day of study: Exam, blood samples

  • 4 weekly appointments until study end

Owner Responsibilities:

  • Cost of diagnostics to determine eligibility (bloodwork, urinalysis, histological/cytological confirmation of the diagnosis)

  • To make and keep all appointments

Financial Incentives:

  • Once enrolled, the study will pay for all costs associated with the study procedures and treatments

  • Study will also cover cost of side effects attributable to the virus treatment or study procedures (up to  $2000/dog/event)

  • A $2500 credit will be applied to the dog's account at the VTH, which can be applied toward further treatments

If you have further questions about any of our clinical trials, please submit an online consulting form. Your consult will then be directed to an appropriate oncology clinician. Requests are typically returned within 5 business days.